Clinical Trial Update: To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC [Phase 2]

View source ↗

Summary

A Phase 2 study concluded to determine the maximum tolerated dose of PEP005 topical gel in patients with superficial basal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• PEP005 Topical Gel (ingenol mebutate)

Snippet

Sponsor: Peplin | Conditions: Superficial Basal Cell Carcinoma | Phase 2 | Status: COMPLETED